Celltrion Pharmaceutical's Godex is on the verge of being expelled from insurance registration, and it is expected to cut voluntary drug prices at the level of comparative drugs as the last defense measure to maintain benefits. The reason why Celltrion Pharmaceutical's strategy is drawing attention is that if Godex, which looks like 60 billion won, is deleted, it is inevitable to lose about 20% of its total sales, which is expected to make every effort to maintain insurance drugs through clinical utility proof. Godex was not recognized for the appropriateness of the benefit at the 7th review of the Pharmaceutical Benefit Evaluation Committee held on the 7th, but the final results may change depending on the evaluation